Korsana Biosciences
PVT · PVT·Waltham, MA·Private·Preclinical
Emerged from stealth in February 2026 with $175M to develop next-gen anti-amyloid therapies for Alzheimer's disease. Proprietary THETA platform uses TfR1-mediated blood-brain barrier shuttle technology for dramatically improved brain drug delivery. Announced reverse merger with Cyclerion Therapeutics (expected Q3 2026) with a $380M PIPE to go public.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Korsana Biosciences Corporate Deck April 2026 | Corporate overview | April 8, 2026 | 31 |